Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Celebrex Stories

2014-03-13 08:28:09

PITTSBURGH, March 13, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Mylan was sued by G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for alleged infringement of this patent in connection with Mylan's Abbreviated New Drug Application (ANDA) for...

2014-03-12 20:24:16

DUBLIN, March 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib)...

2012-05-02 21:20:19

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it. It has been almost eight years since Vioxx® was withdrawn by Merck from the market, provoking an intense controversy about the role inhibitors of the enzyme COX-2 play in causing heart attacks and strokes. Since then,...

2012-04-18 18:20:14

SEOUL, South Korea, April 18, 2012 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate. The study met its primary and secondary endpoints which were to evaluate the safety, analgesic efficacy and functional benefits of CG100649 (2 mg or 4 mg per day) versus Celebrex® (celecoxib) (200 mg per day) over the 4...

efa83c5cafaf4c3bc5304f57d6d835ef
2010-12-02 12:11:43

Reduction Greater than Achieved through Sunscreen A widely used arthritis drug reduces the incidence of non-melanoma skin cancers "“ the most common cancers in humans "“ according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults, led to a 62 percent reduction in non-melanoma skin cancers,...

2010-11-30 21:58:02

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease. The researchers, led by University of Alabama at Birmingham senior scientist and the study's lead author, Craig Elmets, M.D., co-leader of the UAB Comprehensive Cancer Center 's Chemoprevention Program, evaluated the efficacy and safety of celecoxib as a chemo-preventive agent for actinic...

2010-06-17 06:46:00

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin and/or hematocrit...

2010-03-25 09:45:00

NEW YORK, March 25 /PRNewswire/ -- Grant & Eisenhofer, a leading shareholder and corporate governance law firm, was successful in upholding the admission of testimony against pharmaceutical giant Pfizer by six expert witnesses in a rare securities-related Daubert hearing. U.S. District Court Judge Laura Taylor Swain of the United States District Court for the Southern District of New York issued her written ruling on Monday, March 22. Grant & Eisenhofer is representing the class...

2009-12-23 17:29:41

A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots. The research, published in the Proceedings of the National Academy of Sciences (PNAS), indicates that people who are taking aspirin and coxibs together are in fact inhibiting the aspirin's effectiveness in preventing heart attacks and strokes. "This finding strongly suggests that humans who...

a865bf2f0eb46a0ac3a36b9043d1fc541
2009-12-15 14:10:00

Combining celebrex with low-dose aspirin may reduce protection from heart attack and stroke, study suggests Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests. In laboratory studies, University of Michigan researchers found...